Aprea Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aprea Therapeutics generated cash of -$12,177,608, which is more than the previous year. Cash used in financing activities reached the amount of $5,139,990 last year. Net change in cash is therefore -$7,139,110.
Cash Flow
| 2017 | -14.00M | 0 | 23.34M |
|---|---|---|---|
| 2018 | -15.25M | -3.70K | 56.36M |
| 2019 | -26.70M | -30.90K | 92.57M |
| 2020 | -41.80M | -25.70K | 150.94K |
| 2021 | -37.68M | 0 | 1.74M |
| 2022 | -25.01M | 0 | 682.97K |
| 2023 | -12.17M | -93.09K | 5.13M |
APRE Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 28.78M | 53.07M | 89.01M | 130.08M | 65.67M | 24.40M | 13.66M |
Operating activities | |||||||
Net income | -14.28M | -112.66M | -37.12M | -53.47M | -28.05M | -15.52M | -15.19M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 7.05K | 186.44K | 271.67K | 229.61K | 170.25K | 8.31K | 7.93K |
Stock-based compensation expense | 444.45K | 16.98M | 7.81M | 4.98M | 1.34M | 0 | 395.44K |
| Deferred income tax benefit | 444.45K | 16.98M | 7.81M | 4.98M | 1.34M | 0 | 395.44K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 827.46K | -858.51K | -2.73M | 2.32M | 437.51K | 214.38K | 327.05K |
Cash generated by operating activities | -12.17M | -25.01M | -37.68M | -41.80M | -26.70M | -15.25M | -14.00M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -93.09K | 0 | 0 | -25.70K | -30.90K | -3.70K | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -93.09K | 0 | 0 | -25.70K | -30.90K | -3.70K | 0 |
Financing activities | |||||||
Common Stock Issued | 5.78M | 682.97K | 1.53M | 150.94K | 86.90M | 0 | 23.34M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 5.13M | 682.97K | 1.74M | 150.94K | 92.57M | 56.36M | 23.34M |
Net Change In Cash | -7.13M | -24.28M | -35.94M | -41.07M | 64.41M | 41.27M | 10.73M |
Cash at end of period | 21.64M | 28.78M | 53.07M | 89.01M | 130.08M | 65.67M | 24.40M |
| Data source | Data source | Data source | Data source | Data source |